Drug Approval | August 23, 2024
Wanbury receives EIR from FDA for Patalganga facility
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
The facility is a part of Lupin Manufacturing Solutions
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
FDA has concluded that this inspection is 'closed'
Sun Pharma's Dadra facility receives OAI status from US FDA
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
The inspection of the facility conducted from August 7 to August 11, 2023
Subscribe To Our Newsletter & Stay Updated
